Cryoport, Inc.
No enriched coverage for $CYRX in the last 7 days.
Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.
Conestoga Capital Advisors’ Q2 2026 investor letter highlighted Cryoport, Inc. (NASDAQ:CYRX), citing broad-based growth and management’s decision to raise full-year revenue guidance. The letter also noted CYRX’s August 6, 2026 close at $14.71, $741.42 million market cap, and 52-week gain of 94.58%.
Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin
Recent CYRX coverage spans financial news, insider activity and earnings.
In the last 30 days, CYRX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($429K). The most active reporter was SHELTON JERRELL, President, CEO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Earnings call provides fresh operating momentum and profitability progress, with guidance held despite macro/geopolitical uncertainty.
Guidance raise tied to clinical trial portfolio expansion and commercial pipeline could support near-term sentiment and valuation, but the article is investor-letter framing rather than a primary filing.
Results show accelerating Life Sciences Services growth and a profitability milestone, which can re-rate near-term margin expectations.
Insider selling by a senior digital/tech officer is a modest negative signal, but it is not evidence of fundamental deterioration by itself.
Shareholder-vote mechanics for an equity incentive plan amendment can affect dilution expectations and near-term sentiment, but no financial targets or deal terms are disclosed here.
alphai scores every news story that mentions CYRX with an AI model for sentiment and relevance, and aggregates insider trades from Cryoport, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.
6 min readConestoga Capital Advisors’ Q2 2026 investor letter highlighted Cryoport, Inc. (NASDAQ:CYRX), citing broad-based growth and management’s decision to raise full-year revenue guidance. The letter also noted CYRX’s August 6, 2026 close at $14.71, $741.42 million market cap, and 52-week gain of 94.58%.
6 min readCryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin
4 min readZECCHINI EDWARD J (Chief Digital and Tech Officer) sold 35,000 shares of Cryoport, Inc. (CYRX) at an average of $14.50 ($14.47–$15.23, $0.51M total) across 2 trades over 2026-06-10 to 2026-06-11.
2 min readCryoport, Inc. (CYRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 tm2617057d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Cryoport, Inc. 2018 Omnibus Equity Incentive Plan (as amended by the First Amendment (effective February 25, 2021), the Second Amendment (effective April 30, 2021), the Third Amendment (effective May 17, 2024), and the Fo
2 min readSTEFANOVICH ROBERT (Chief Financial Officer) sold 169,427 shares of Cryoport, Inc. (CYRX) at $16.27 ($2.76M total) on 2026-06-04.
2 min readMandalam Ramkumar sold 23,214 shares of Cryoport, Inc. (CYRX) at $15.44 ($0.36M total) on 2026-06-08.
1 min readCryoport Inc (CYRX) reported Q1 2026 revenue that exceeded analyst estimates, despite continued net losses, navigating a volatile market for cell and gene therapy logistics. The company specializes in temperature-controlled logistics and biostorage, positioning itself as an infrastructure partner for the advanced therapies sector. Its performance reflects strong demand in core service lines amidst growth investments and cost pressures.
4 min readInsiders at Cryoport (NASDAQ: CYRX) sold US$1.6 million worth of shares over the last year, with Chairman Jerrell Shelton making the largest individual sale. This occurred despite recent stock gains, and the selling price was even below the current market value, suggesting insiders may have viewed a lower price as reasonable. While insiders still collectively own a notable 3.6% of the company, the consistent selling without any purchases raises concerns about their confidence in the stock's future performance.
3 min readCryoPort's CFO, Robert Stefanovich, recently sold 2,743 shares of the company's stock for $8.00 per share, totaling $21,944, reducing his holdings by 0.97%. This follows a previous sale of 38,700 shares on March 12th. Despite mixed analyst ratings, the consensus is a "Moderate Buy" with a target price of $12.94.
2 min read
